Abstract：Objective To investigate the clinical effect of Metformin as adjuvant therapy for treatment of patients with polycystic ovary syndrome (PCOS).Methods Thirty patients with PCOS who came to our hospital from March 2015 to June 2017 were selected as subjects of study.They were divided into control group and study group according to the random number table method,15 cases in each group.The control group was treated with Dydrogesterone,while the study group was added with Metformin besides Dydrogesterone.The clinical efficacy,tumor necrosis factor-α (TNF-α),homeostasis model assessment-insulin resistance (HOMA-IR),serum estradiol (E2),follicle stimulating hormone (FSH),testosterone(T),luteinizing hormone(LH),and the occurrence of adverse reactions were compared between the two groups.Results The clinical effective rate of the study group was 93.33%,higher than that of the control group accounting for 60.00%，the difference was statistically significant (P＜0.05).There were no significant differences in HOMA-IR,TNFα,LH,FSH,T and E2 levels between the two groups before intervention (P＞0.05).After intervention,HOMA-IR,TNFα,LH,FSH,T,and E2 level were lower than those before the intervention,and those indexes in study group were lower than those of the control group，the differences were statistically significant (P＜0.05).There was no significant difference in the incidence of adverse reactions between the study group (13.33%) and the control group (20.00%) (P＞0.05).Conclusion Metformin is effective in the treatment of PCOS with Dexamethasone,which can improve IR,inflammatory status and endocrine metabolism in patients.
京公网安备 11010502046607号